Drug Profile
N-Glycolyl GM3 cancer vaccine - Center of Molecular Immunology/Recombio
Alternative Names: CIMAVaxG vaccine; N-glicolil GM3/VSSP; N-Glycolyl GM3/Vssp vaccine; N-glycolyl therapeutic vaccine; N-GlycolylGM3/VSSP/Montanide-ISA-51-vaccine; NGcGM3/VSSP vaccineLatest Information Update: 16 Apr 2021
Price :
$50
*
At a glance
- Originator Center of Molecular Immunology
- Developer Center of Molecular Immunology; Recombio
- Class AIDS vaccines; Cancer vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Breast cancer
- Phase II Malignant melanoma
Most Recent Events
- 16 Apr 2021 N-Glycolyl GM3 cancer vaccine is still in phase II trial for Malignant melanoma (Metastatic disease, Second-line therapy or greater) in Cuba (RPCEC00000223)
- 16 Apr 2021 N-Glycolyl GM3 cancer vaccine is still in phase II/III trial for Breast cancer in Cuba (RPCEC00000070)
- 13 Dec 2017 Center of Molecular Immunology plans a clinical trial in Non-small cell lung cancer (Combination with Nimotuzumab, Late-stage disease) in Cuba (SC) (RPCEC00000270)